Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at whether the combination of lower-dose chemotherapy
with two chemotherapy (anti-cancer) drugs, called busulfan and melphalan, and an antibody
medication called alemtuzumab (Campath®), can prevent rejection of donor blood stem cells so
that those cells take hold and build a healthy new blood cell factory after transplant. The
study will also look at the safety of the combination of drugs and of the transplant of
peripheral blood stem cells from a healthy relative or an unrelated donor.